Swedish court rules CBD does not make a product pharmaceutical

A Swedish court has ruled that a product containing CBD for oral consumption cannot automatically be classified as a pharmaceutical, but that the legal status of each product must be assessed individually

Unlock access

Want the full analysis? Let's talk

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

Corporate Email*

Company Name*

Name*

Department*

Industry*

Work Telephone*

How did you hear about us?*

Tell us what you're interested in*

This field is for validation purposes and should be left unchanged.

I'm already a subscriber

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

LATEST ALERTS

Swedish court rules CBD does not make a product pharmaceutical

CannIntelligence

Our Key Benefits

Sign up to our newsletter

LATEST ALERTS

Want the full analysis? Let's talk

CannIntelligence

Our Key Benefits

Want the full analysis? Let's talk

Sign up to our newsletter

Start your FREE trial